glp 1 stock GLP-1 Activator Insurers struggle with GLP-1 costs;

Certification complexity favors manufacturers and pharmacy partners with established regulatory expertise and scalable compliance systems, reinforcing the position of large pharmaceutical players and licensed specialty pharmacies

Semaglutide Started as a diabetes therapy

Wegovy (semaglutide) prescribing information: breastfeeding precautions

As the report observes, M&A may be playing a relatively greater role given some pharmas need to replace genericising blockbusters. The first half of 2024 saw close to $100 billion worth of Big Pharma M&A, putting this year on track to surpass 2023 itself one of the top-three strongest M&A years in two decades